ROLE OF ENDOTHELIAL INFLAMMATION IN DEMYELINATING DISEASES OF THE CENTRAL NERVOUS SYSTEM - TREMEND

Department of Neurology0 个研究点目标入组 50 人开始时间: 2014年3月28日最近更新: 2019年12月10日

试验速览

暂无简介。

•Inclusion Criteria
•To be eligible to participate in this study, candidates must meet the following eligibility criteria at
•the Screening/Baseline Visit:
•Patients with relapsing remitting multiple sclerosis (RRMS) fulfilling the McDonald criteria.
•Treatment-naïve patients and patients treated with first-line disease modifying treatment
•Age 18-60 years.
•EDSS 1-5.5.
•Participants must be able to transport self.
•Signed informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Exclusion Criteria
•Candidates will be excluded from study entry if any of the following exclusion criteria exist at the
•Screening/Baseline Visit:
•MS relapse or change in DMT within 60 days.
•Diagnosis of primary progressive, secondary progressive or progressive relapsing MS.
•Cancer within five years.
•ALAT above 90 U/l, BASP above 210 U/l, gamma-GT above 230 U/l.
•Pregnancy or lactation.

发起方